论文部分内容阅读
近年来抗肿瘤血管生成治疗逐渐成为肺癌靶向治疗的热点。前不久刚结束的2006年ASCO大会公布了贝伐单抗及小分子血管内皮生长因子受体(VEGFR)酪氨酸激酶抑制剂(TKI)的研究新进展,其结果令人鼓舞。VEGF是一种细胞因子,它能诱导内皮细胞增生、蛋白酶的表达、抗内皮细胞凋亡和细胞
In recent years, anti-tumor angiogenesis therapy has become a hot target of targeted therapy of lung cancer. The 2006 ASCO Conference, which was just concluded shortly before, announced the latest advances in the study of bevacizumab and the small molecule vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitor (TKI), and the results are encouraging. VEGF is a cytokine that induces endothelial cell proliferation, protease expression, anti-endothelial cell apoptosis, and cellular